EUVIMEDEUVIMED entdecken
Crossref

Discovery of Pyrrolopyrazine Carboxamide Derivatives as Potent and Selective FGFR2/3 Inhibitors that Overcome Mutant Resistance

Yazhou Wang, Yihong Zhang, Jinxin Liu, Jichen Zhao, Chao Wang, Fanye Meng, Xin Cai, Man Zhang, Alex Aliper iD, Tao Liang, Feng Yan, Feng Ren iD und 5 weitere

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.4c03205 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Yazhou Wang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Insilico Medicine Shanghai Ltd, Suite 901, Tower C, Changtai Plaza, 2889 Jinke Road, Pudong New District, Shanghai 201203, China. Hauptthemen laut MEDLINE: Receptor, Fibroblast Growth Factor, Type 2, Receptor, Fibroblast Growth Factor, Type 3, Protein Kinase Inhibitors. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fibroblast growth factor receptors (FGFRs) are established oncogenic drivers in various solid tumors. However, the approved FGFR inhibitors face challenges with acquired resistance and dose-limiting adverse effects associated with FGFR1/4 inhibition, limiting therapeutic efficacy. Herein, we systematically explored linker and electrophile moieties based on the pyrrolopyrazine carboxamide core and identified aniline α-fluoroacrylamide as an effective covalent warhead. Compound 10 potently inhibited FGFR2 and FGFR3, even in the context of common inhibitor-resistance mutations, including in the gatekeeper, molecular brake, and activation loop regions. Compound 10 spared FGFR1/4 and other kinases without causing diarrhea and serum phosphate elevation in vivo . Oral administration of compound 10 induced tumor stasis or regression in the SNU-16 gastric cancer model with favorable pharmacokinetics and robust pharmacodynamic suppression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, Fibroblast Growth Factor, Type 2Receptor, Fibroblast Growth Factor, Type 3Protein Kinase InhibitorsHumansAnimalsStructure-Activity RelationshipDrug Resistance, NeoplasmMiceMutationPyrazinesPyrrolesAntineoplastic AgentsCell Line, TumorDrug DiscoveryRatsStomach NeoplasmsMice, Nude

Substanzen

Receptor, Fibroblast Growth Factor, Type 2Receptor, Fibroblast Growth Factor, Type 3FGFR2 protein, humanProtein Kinase InhibitorsFGFR3 protein, humanPyrazinesPyrrolesAntineoplastic Agents

Autor:innen und Institutionen

  • Insilico Medicine Shanghai Ltd, Suite 901, Tower C, Changtai Plaza, 2889 Jinke Road, Pudong New District, Shanghai 201203, China.
  • GenFleet Therapeutics (Shanghai) Inc., Shanghai 201203, China.
  • Insilico Medicine AI Limited, Masdar City, Abu Dhabi 145748, UAE.

ORCID-Profile: Alex Aliper, Feng Ren, Alex Zhavoronkov, Xiao Ding

Zitieren

APA

Wang, Y., Zhang, Y., Liu, J., Zhao, J., Wang, C., Meng, F., Cai, X., Zhang, M., Aliper, A., Liang, T., Yan, F., Ren, F., Lan, J., Lu, Q., Zhou, F., Zhavoronkov, A., & Ding, X. (2025). Discovery of Pyrrolopyrazine Carboxamide Derivatives as Potent and Selective FGFR2/3 Inhibitors that Overcome Mutant Resistance. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c03205

Vancouver

Wang Y, Zhang Y, Liu J, Zhao J, Wang C, Meng F, et al. Discovery of Pyrrolopyrazine Carboxamide Derivatives as Potent and Selective FGFR2/3 Inhibitors that Overcome Mutant Resistance. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c03205

BibTeX
@article{Wang2025,
  author = {Wang, Yazhou and Zhang, Yihong and Liu, Jinxin and Zhao, Jichen and Wang, Chao and Meng, Fanye and Cai, Xin and Zhang, Man and Aliper, Alex and Liang, Tao and Yan, Feng and Ren, Feng and Lan, Jiong and Lu, Qiang and Zhou, Fusheng and Zhavoronkov, Alex and Ding, Xiao},
  title = {Discovery of Pyrrolopyrazine Carboxamide Derivatives as Potent and Selective FGFR2/3 Inhibitors that Overcome Mutant Resistance},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.4c03205}
}
Kostenlos starten →